TY - CHAP M1 - Book, Section TI - Telavancin, Dalbavancin, Oritavancin A1 - Gruenberg, Katherine A1 - Guglielmo, B. Joseph A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. PY - 2023 T2 - Current Medical Diagnosis & Treatment 2023 AB - Telavancin was the first approved lipoglycopeptide for the treatment of skin and soft tissue infection due to resistant gram-positive bacterial pathogens. It is indicated as an alternative to vancomycin in skin and soft tissue infection and hospital-acquired and ventilator-associated bacterial pneumonia. Telavancin displays concentration-dependent bactericidal killing and a 7.5-hour half-life and post-antibiotic effect of 4–6 hours allowing for once-daily dosing. Taste disturbance, nausea, headache, foamy urine, prolonged QT, and reversible kidney injury are the most commonly observed adverse events. Telavancin has a boxed warning highlighting the increased mortality in patients with preexisting kidney dysfunction (creatinine clearance 50 mL/min or less). Similar to daptomycin and linezolid, telavancin is useful in the treatment of resistant bacterial infection as an alternative for patients who are intolerant of vancomycin. However, the increased mortality risk in certain patients suggests it should serve a secondary role in the treatment of serious gram-positive infection. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=1193122193 ER -